Navigation Links
High Growth Potential for Carotid Stent and Thoracic Aortic Stent Graft Markets
Date:5/20/2008

Procedural growth could increase by more than 20% over the next five years,

according to Millennium Research Group

WALTHAM, Mass., May 20 /PRNewswire/ -- According to Millennium Research Group's US Markets for Peripheral Vascular (PV) Devices 2008 report, the thoracic aortic stent graft market is poised to exceed 20% growth over the next five years. Carotid stents are another PV device segment with significant potential, although market expansion in this area is dependent on positive clinical trial data and expanded Centers for Medicare & Medicaid Services (CMS) reimbursement.

Treatment of thoracic aortic disease, a PV condition, is expected to witness a surge over the next five years as manufacturers focus on developing aortic stent grafts specific to this indication. The thoracic aorta is extremely risky to treat surgically because of the high mortality associated with this procedure; thus, the availability of a minimally invasive alternative -- thoracic endovascular aortic repair (TEVAR)-- has garnered a lot of attention among physicians and represents a significant opportunity for market expansion. Next-generation thoracic stent grafts, and clinical trials supporting their efficacy, will expand the treatable patient population, leading to growth in procedures in excess of 20% over the next five years.

Growth in carotid artery stenting procedures slowed to less than 5% per year in 2007 due to a lack of conclusive data supporting the safety and efficacy of the procedure compared to surgical alternatives. Compounding this lack was the CMS decision to not expand reimbursement coverage to include select asymptomatic carotid artery disease patients. In early 2008, CMS decided, however, to reexamine the expansion to reimbursement. If expanded reimbursement is approved, and the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) trial yields favorable results for stenting, carotid stenting growth could jump
'/>"/>

SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. OmniGuide(R) Secures $25 Million in Funding to Support Continued Growth and New Market Penetration
2. Diabetes Drugs Emerge as Top Force in Drug Spending Growth
3. Amil Has Strong Growth With High Profitability
4. Hill-Rom Reports Second Quarter Revenue Growth of 12.0 Percent to $375.2 Million and Adjusted Earnings Per Fully Diluted Share from Continuing Operations of $0.26, Unchanged from the Prior Year
5. New Data Shows Continued Growth of Long-Term Disability Claims and Decline in Social Security Disability Insurance Applications Approval Rate
6. PAREXEL International to Present at Robert W. Bairds 2008 Growth Stock Conference
7. Matrixx Initiatives, Inc. Announces Fiscal 2008 Revenue of $101 Million and Net Income Growth of 59% to $10.4 Million, or $1.04 Earnings Per Share Versus $0.66 in the Prior Year
8. Booth Joins PrePak Systems for Growth, Expansion
9. Neurotechnology Industry Reports Record Global Growth of $130.5 Billion in 2007
10. Some Weight-Loss Drugs Might Disrupt Brain Growth in Kids
11. Symposium Targets Critical Manufacturing Topics for Emerging Growth Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...ert Pathologists Discuss the Latest Developments i...RTHFIELD, Ill., Sept. 5 /PRNewswire-USNewswire/ --...point. Molecular testing and the promise,of person...reated. Digital,slides and other imaging technolog...lege of American Pathologists is taking a leadersh...
(Date:9/5/2008)...hers explain how theoretical ,anti-cloak, could br...pt. 5 (HealthDay News) -- Just in case someone dev...cientists say they know how to uncloak the objects... Optics Express , certain materials underneath an ...o be seen again. , Researchers at Shanghai Jiao...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- Speake...y in support of the aims of the "Stand,Up to Cance... "There is not a person in our country who has no...r kills 565,000 Americans annually, and each,year ...ricans must work,together to make eradicating the ...
(Date:9/5/2008)...HINGTON, Sept. 5 /PRNewswire-USNewswire/ -- U.S. c...r relief to Cuban victims of Hurricane,Gustav, whi...s., (http://www.PanAmericanRelief.org ), "Donatio...perately need,after this natural disaster," says M... Initiative at the Pan American Development Founda...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:Cuban Disaster Relief Donations Sought in the Wake of Hurricane Gustav 2
...tbreak in the Sydney CBD is linked to the Royal Au...lth authorities suspect//. However, they could not... fatal disease caused by a bacteria belonging to t...philia, have been reported in NSW this month, incl...
...searchers at the University of Illinois at Urbana-... image-forming method // that is used for optical ...three-dimensional images from hazy and unclear dat...ic Synthetic Aperture Microscopy, ISAM is benefici...
...he EU's 27 member states decided that milk and mea... be considered in the same way as any other novel ...n Commission's Novel Foods Working Group, after Eu...oned food debate because of news that the offsprin...
... discovered that activation of a particular brain ...or altruistic.// The results of this Duke Universi...ay, Jan 21 online edition of Nature Neuroscience. ...f this brain region may not necessarily identify w...
Other Medicine News:Health News:New Computed Imaging Technique Uses Hazy Images to Improve View 2Health News:EU States Agree on Clone Food Plan 2Health News:Activation of a Particular Brain Region Predicts Altruism: Study 2
(Date:9/3/2008)...s Phase 3 Plans with FDA, PRINCETON, N.J., Sept. ...ced today that it successfully completed two key c... new, innovative low-dose, once-weekly,contracept...rnal product,code AG-200-15. The Phase 2b safety a...point of ovulation suppression, cycle control and ...
(Date:9/3/2008)...trong Evidence Pycnogenol(R) Lowers Joint, Pain, S...lowing Cessation of th... According to the Center for,Disease Control (CDC)...s,is on the rise. A new study published in the Au...nogenol(R), bark extract from the French maritime ...
(Date:9/3/2008)...wswire-FirstCall/ -- A sub-analysis of,the TRITON-...prasugrel,compared with clopidogrel significantly ... (7.4 percent vs. 9.7 percent, p<0.0001), regardle...of an artery-opening,procedure known as percutaneo...d spontaneously during the longer-term maintenance...
(Date:9/2/2008)...-FirstCall/ --, - This Analysis Showed That Multa... 34% in Patients With Atrial Fibrillation or Atria...otic Therapy, The results of a post-hoc analysis ...oday at the clinical trial update session of the E...nich, Germany. Previous results,from the landmark ...
Breaking Medicine Technology:Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 2Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 3Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 4Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 5Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel 6Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Sinexus Welcomes New CEO and Completes Series B 21149 1Sinexus Welcomes New CEO and Completes Series B 21149 2Sinexus Welcomes New CEO and Completes Series B 21149 3Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi Center Radiation Therapy Systems Agreement 21144 1Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi Center Radiation Therapy Systems Agreement 21144 2Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi Center Radiation Therapy Systems Agreement 21144 3Summer is for Sleeping 3F Exhausted Americans Challenged to Sleep in on Longest Day of the Year 21139 1Summer is for Sleeping 3F Exhausted Americans Challenged to Sleep in on Longest Day of the Year 21139 2Summer is for Sleeping 3F Exhausted Americans Challenged to Sleep in on Longest Day of the Year 21139 3Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 1Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 2Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 3Spradling receives Gruber Foundation Genetics Prize for new genetic techniques 3537 4
...zed phase II/III clinical trial,anticipated later ...tCall/ -- Cell,Therapeutics, Inc. (CTI) announced ...nstrate that treatment with pixantrone (BBR,2778) ...ty, while,doxorubicin and mitoxantrone induced sig...cardiac side effects of equiactive doses,of pixant...
...WIRE)--Jun 26, 2007 - Sirtris,Pharmaceuticals, Inc...sed on discovering and developing small molecule d...hat activation of SIRT1, a,member of the sirtuin f...rodegenerative diseases such as Alzheimer,s Diseas...ls. These findings,appear in an article published ...
Other Medicine Technology:Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 2Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 3Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 4Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 5Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone 6Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease 2Resveratrol Studies Suggest Broad Implications for SIRT1 Activation,in Neurodegenerative Diseases of Aging Such as Alzheimer's Disease 3
High sensitive, specific one step immunochromatographic assay for human infectious disease
Span Diagnostics Limited
Malaria (P. fal.) Ag Rapid Test
OptiMAL is a malaria test, for diagnosis and therapy control of an infection by Plasmodium species (Malaria).
Medicine Products: